MITE in the Treatment of Dyspepsia After Cholecystectomy
MITE in the Treatment of Dyspepsia After Cholecystectomy
To confirm the clinical efficacy of Compound Azintamide Enteric-coated Tablets in the
 treatment of patients with dyspepsia after cholecystectomy (such as abdominal distension,
 abdominal pain/abdominal discomfort, diarrhea/fatty stool, early satiety, belching, loss of
 appetite, etc.) by comparing with positive control drug, to observe its safety, and to
 evaluate the quality of life of subjects before and after treatment
This study is a multi-center, randomized, superiority and parallel controlled clinical study.
 Third-party institutions will generate random codes according to random numbers of the
 software and divide them into two groups (Compound Azintamide Enteric-coated Tablets Group,
 Oryz-aspergillus Enzyme and Pancreatin Tablet and Ursodeoxycholic Acid Tablets Group) in a
 ratio of 1:1. Random numbers will be sealed and stored in radiopaque envelopes, which will be
 managed by a designated person not involved in the specific study.

 Specific intervention measures: If dyspeptic symptoms occur after laparoscopic
 cholecystectomy and are randomized, the experimental group takes Compound Azintamide
 Enteric-coated Tablets, and the control group takes Oryz-aspergillus Enzyme both Pancreatin
 Tablet and Ursodeoxycholic Acid Tablets. They were registered before medication and on days
 14 and 28 after medication, and gastrointestinal symptoms were assessed at each follow-up
 visit
Inclusion Criteria:

 1. Aged 18-70 years old, male or female;

 2. Patients after laparoscopic cholecystectomy, mainly including cholecystectomy due to
 cholecystitis, gallstones, gallbladder polyps and other benign gallbladder tumors,
 non-functioning gallbladder;

 3. Dyspeptic symptoms occurred 2 weeks after laparoscopic cholecystectomy, including:
 abdominal distension, abdominal pain/abdominal discomfort, diarrhea/fatty stool, early
 satiety, belching, loss of appetite;

 4. Signed informed consent, agreed to participate in this study.

 Exclusion Criteria:

 1. Patients with abnormal liver function and renal function;

 2. Patients with severe heart and lung dysfunction;

 3. Patients with neurological, mental illness or other reasons can not cooperate with the
 study;

 4. Patients with advanced malignant tumors or other serious wasting diseases, any
 unstable chronic diseases and acute diseases, interfere with the efficacy evaluation
 of this study (such as patients undergoing chemotherapy) and the completion of the
 trial plan;

 5. Patients with biliary obstruction, acute hepatitis, etc., do not use the test drugs
 and control drugs, and allergic to the test drugs and control drugs;

 6. Patients who have taken digestive enzymes and cholagogue drugs by themselves;

 7. Pregnant and lactating women;

 8. Patients who are participating in other clinical trials;

 9. Patients who cannot be followed up on time.

 Elimination Criteria

 1. Failure to take medicine as required, that is,Failure to take medicine or missed doses
 ≥ 3 times within 1week;

 2. Taking other digestive enzymes, cholagogues and prokinetic drugs or drugs affecting
 digestive enzymes and bile secretion and excretion during the study;

 3. Adverse events occur, for the benefit of patients, doctors believe that the drug
 should not be continued; the results of such cases do not participate in the efficacy
 statistics, but are related to the safety evaluation.

 Drop-out Criteria

 1. Cases with adverse events and patients are not willing to continue participating in
 the study.

 2. Cases who voluntarily withdrew consent from the study due to poor efficacy and
 inconvenience in follow-up.

 3. cases lost to follow-up due to various reasons.